









Markets
/
Stocks
/
nasdaq-cphi
/

China Pharma Holdings Inc

CPHI

1.554USD

-0.076-4.66%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

5.07MMarket Cap

LossP/E TTM



China Pharma Holdings Inc

1.554

-0.076-4.66%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of China Pharma Holdings Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

China Pharma Holdings Inc's Score

Industry at a Glance

Industry Ranking

130 / 159

Overall Ranking

469 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

China Pharma Holdings Inc Highlights

StrengthsRisks

China Pharma Holdings Inc is a company principally engaged in the development, manufacture and marketing of pharmaceutical products. The Company's products are for human use in connection, and with a variety of high-incidence and high-mortality diseases and medical conditions prevalent. The Company manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. In addition, the Company is also engaged in the production of comprehensive healthcare products and protective products.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.53M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 4.53M.

Fairly Valued

The company’s latest PE is -1.04, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 118.68K shares, increasing 38.22% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.66, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.03M, representing a year-over-year increase of 10.90%, while its net profit experienced a year-over-year increase of 63.26%.

Score

Industry at a Glance

Previous score

6.66

Change



Financials

5.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.82

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.98

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

China Pharma Holdings Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 8.60, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -1.04, which is -75.32% below the recent high of -0.26 and -1382.49% above the recent low of -15.47.

Score

Industry at a Glance

Previous score

8.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 130/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.77.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 2.71, which is lower than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 1.86 and the support level at 1.39, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.69

Change

0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.055

Sell

RSI(14)

32.597

Neutral

STOCH(KDJ)(9,3,3)

13.461

Sell

ATR(14)

0.084

Low Volatility

CCI(14)

-173.687

Sell

Williams %R

94.000

Oversold

TRIX(12,20)

-0.429

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.666

Sell

MA10

1.705

Sell

MA20

1.786

Sell

MA50

1.787

Sell

MA100

1.731

Sell

MA200

1.900

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Li (Zhilin)

302.76K

Liu (Tao Chengdu)

300.00K

UBS Financial Services, Inc.

71.23K

+581.79%

Citadel Advisors LLC

23.07K

+334.79%

Tsui (Heung Mei)

18.63K

HRT Financial LP

16.17K

+543.89%

Tower Research Capital LLC

8.21K

Two Sigma Investments, LP

-100.00%

XTX Markets LLC

-100.00%

Citi Investment Research (US)

-100.00%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.49, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 1.04. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.